Dominari (DOMH)
Market Price (9/7/2026): $2.14 | Market Cap: $48.7 MilSector: Financials | Industry: Diversified Capital Markets
Dominari (DOMH)
Market Price (9/7/2026): $2.14Market Cap: $48.7 MilSector: FinancialsIndustry: Diversified Capital Markets
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -52% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 124% Attractive yieldDividend Yield is 50% | Weak multi-year price returns3Y Excs Rtn is -78% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -43 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -32% Weak revenue growthRev Chg QQuarterly Revenue Change % is -57% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -13% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -99% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -52% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 124% |
| Attractive yieldDividend Yield is 50% |
| Weak multi-year price returns3Y Excs Rtn is -78% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -43 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -32% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -57% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -13% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -99% |
Qualitative Assessment
AI Analysis | Feedback
Dominari (DOMH) stock has lost about 45% since 5/31/2026 because of the following key factors:
1. Significant Decline in Fiscal Q2 2026 Revenue. Dominari Holdings Inc. experienced a substantial decrease in revenue, with fiscal Q2 2026 (ended June 30, 2026) revenue reported at $16.79 million, a 57% drop compared to $38.91 million in fiscal Q2 2025. This decline was primarily attributed to fewer underwriting closings, lower carried interest, and weaker principal transactions.
2. Shift from Profit to Substantial Net Loss. The company reported a net loss attributable to common stockholders of $5.4 million in fiscal Q2 2026, a significant reversal from a net income of $16.6 million in the prior-year quarter. Furthermore, the year-to-date net loss for the first half of fiscal 2026 widened considerably to $62.8 million, compared to a net loss of $15.9 million in the first half of fiscal 2025.
Show more
Dominari (DOMH) stock has lost about 45% since 5/31/2026 because of the following key factors:
1. Significant Decline in Fiscal Q2 2026 Revenue. Dominari Holdings Inc. experienced a substantial decrease in revenue, with fiscal Q2 2026 (ended June 30, 2026) revenue reported at $16.79 million, a 57% drop compared to $38.91 million in fiscal Q2 2025. This decline was primarily attributed to fewer underwriting closings, lower carried interest, and weaker principal transactions.
2. Shift from Profit to Substantial Net Loss. The company reported a net loss attributable to common stockholders of $5.4 million in fiscal Q2 2026, a significant reversal from a net income of $16.6 million in the prior-year quarter. Furthermore, the year-to-date net loss for the first half of fiscal 2026 widened considerably to $62.8 million, compared to a net loss of $15.9 million in the first half of fiscal 2025.
3. Deterioration of Financial Health and Shareholder Dilution. Dominari's stockholders' equity markedly declined to $21.9 million at June 30, 2026, from $69.4 million at December 31, 2025. Concurrently, the outstanding share count increased to 24.2 million at June 30, 2026, up from 16.1 million at December 31, 2025, indicating dilution for existing shareholders.
4. Negative Analyst Sentiment and Forecasts. Analysts have issued a consensus "Sell" rating for Dominari, with its valuation considered "Expensive" based on AAII's Value Grade. Technical analysis indicates a "Sell Candidate" rating with a score of -4.90 as of August 28, 2026, and a short-term price forecast that projects a further significant decrease, with an average analyst price target indicating a potential 79.87% decline from the August 2026 price.
Show less
Stock Movement Drivers
Fundamental Drivers
The -43.2% change in DOMH stock from 5/31/2026 to 9/6/2026 was primarily driven by a -20.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312026 | 9062026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.70 | 2.10 | -43.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 156 | 133 | -14.2% |
| P/S Multiple | 0.4 | 0.4 | -16.7% |
| Shares Outstanding (Mil) | 18 | 23 | -20.6% |
| Cumulative Contribution | -43.2% |
Market Drivers
5/31/2026 to 9/6/2026| Return | Correlation | |
|---|---|---|
| DOMH | -43.2% | |
| Market (SPY) | 1.8% | 42.7% |
| Sector (XLF) | 12.6% | 4.6% |
Fundamental Drivers
The -24.6% change in DOMH stock from 2/28/2026 to 9/6/2026 was primarily driven by a -32.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 9062026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.79 | 2.10 | -24.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 106 | 133 | 25.5% |
| P/S Multiple | 0.4 | 0.4 | -11.5% |
| Shares Outstanding (Mil) | 15 | 23 | -32.1% |
| Cumulative Contribution | -24.6% |
Market Drivers
2/28/2026 to 9/6/2026| Return | Correlation | |
|---|---|---|
| DOMH | -24.6% | |
| Market (SPY) | 12.6% | 47.9% |
| Sector (XLF) | 13.6% | 16.7% |
Fundamental Drivers
The -59.6% change in DOMH stock from 8/31/2025 to 9/6/2026 was primarily driven by a -72.3% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9062026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.20 | 2.10 | -59.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 60 | 133 | 124.0% |
| P/S Multiple | 1.3 | 0.4 | -72.3% |
| Shares Outstanding (Mil) | 15 | 23 | -34.8% |
| Cumulative Contribution | -59.6% |
Market Drivers
8/31/2025 to 9/6/2026| Return | Correlation | |
|---|---|---|
| DOMH | -59.6% | |
| Market (SPY) | 20.4% | 46.0% |
| Sector (XLF) | 8.9% | 29.2% |
Fundamental Drivers
The -7.6% change in DOMH stock from 8/31/2023 to 9/6/2026 was primarily driven by a -99.8% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 9062026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.27 | 2.10 | -7.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 133 | 187918.3% |
| P/S Multiple | 154.5 | 0.4 | -99.8% |
| Shares Outstanding (Mil) | 5 | 23 | -78.8% |
| Cumulative Contribution | -7.6% |
Market Drivers
8/31/2023 to 9/6/2026| Return | Correlation | |
|---|---|---|
| DOMH | -7.6% | |
| Market (SPY) | 77.1% | 25.0% |
| Sector (XLF) | 76.6% | 18.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DOMH Return | -33% | -67% | -21% | -62% | 443% | -49% | -82% |
| Peers Return | 55% | 36% | 6% | 44% | 3% | -3% | 218% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| DOMH Win Rate | 25% | 33% | 58% | 17% | 58% | 22% | |
| Peers Win Rate | 75% | 67% | 67% | 75% | 46% | 58% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| DOMH Max Drawdown | -76% | -71% | -58% | -71% | -73% | -52% | |
| Peers Max Drawdown | -18% | -25% | -29% | -33% | -26% | -43% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IOND, PWCM, VIP, LPLA, CRCL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/4/2026 (YTD)
How Low Can It Go
| Event | DOMH | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -20.6% | -7.8% |
| % Gain to Breakeven | 26.0% | 8.5% |
| Time to Breakeven | 32 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.1% | -9.5% |
| % Gain to Breakeven | 64.3% | 10.5% |
| Time to Breakeven | 156 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -42.3% | -6.7% |
| % Gain to Breakeven | 73.4% | 7.1% |
| Time to Breakeven | 630 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -55.9% | -24.5% |
| % Gain to Breakeven | 126.8% | 32.4% |
| Time to Breakeven | 983 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -49.3% | -33.7% |
| % Gain to Breakeven | 97.3% | 50.9% |
| Time to Breakeven | 108 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -31.5% | -3.7% |
| % Gain to Breakeven | 46.0% | 3.9% |
| Time to Breakeven | 20 days | 6 days |
In The Past
Dominari's stock fell -20.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 26.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | DOMH | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -20.6% | -7.8% |
| % Gain to Breakeven | 26.0% | 8.5% |
| Time to Breakeven | 32 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.1% | -9.5% |
| % Gain to Breakeven | 64.3% | 10.5% |
| Time to Breakeven | 156 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -42.3% | -6.7% |
| % Gain to Breakeven | 73.4% | 7.1% |
| Time to Breakeven | 630 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -55.9% | -24.5% |
| % Gain to Breakeven | 126.8% | 32.4% |
| Time to Breakeven | 983 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -49.3% | -33.7% |
| % Gain to Breakeven | 97.3% | 50.9% |
| Time to Breakeven | 108 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -31.5% | -3.7% |
| % Gain to Breakeven | 46.0% | 3.9% |
| Time to Breakeven | 20 days | 6 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -42.1% | -17.9% |
| % Gain to Breakeven | 72.7% | 21.8% |
| Time to Breakeven | 2 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -20.7% | -15.4% |
| % Gain to Breakeven | 26.1% | 18.2% |
| Time to Breakeven | 77 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -84.0% | -53.4% |
| % Gain to Breakeven | 525.0% | 114.4% |
| Time to Breakeven | 143 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -26.9% | -8.6% |
| % Gain to Breakeven | 36.7% | 9.5% |
| Time to Breakeven | 773 days | 47 days |
In The Past
Dominari's stock fell -20.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 26.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Dominari (DOMH)
Dominari, trading under the symbol DOMH, is a biotechnology company primarily focused on the discovery and development of small-molecule therapeutics. The company's core mission is to address significant unmet medical needs by creating innovative treatments for various types of cancer and infectious viral diseases, leveraging scientific research and development.
A key area of Dominari's business is its oncology pipeline, which features several anti-cancer drug candidates. Notable examples include DHA-dFdC, a drug candidate in development for pancreatic cancer, and KPC34, a small molecule treatment being advanced for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The company's therapeutic development extends to other cancers, including prostate cancer, indicating a broad commitment to oncology.
Beyond cancer, Dominari is also developing an antiviral platform designed to inhibit the replication of a wide range of viruses. This includes well-known pathogens such as the influenza virus, Ebolavirus, Marburg virus, and various coronaviruses like SARS-CoV, MERS-CoV, and SARS-CoV-2. The ultimate customers for Dominari's potential products are patients suffering from these life-threatening conditions, with the company serving the global pharmaceutical and healthcare markets.
AI Analysis | Feedback
- An early-stage Amgen or Gilead Sciences, but focused on developing new small-molecule drugs for cancers and viruses.
- A research-driven Moderna or BioNTech, but for small-molecule cancer and antiviral treatments instead of vaccines.
AI Analysis | Feedback
- DHA-dFdC: A drug candidate currently in development for the treatment of pancreatic cancer.
- KPC34: A small molecule treatment under development for acute myeloid leukemia and acute lymphoblastic leukemia.
- Antiviral platform: A developing technology designed to inhibit the replication of various viruses, including influenza, Ebolavirus, and coronaviruses.
AI Analysis | Feedback
Based on the provided information, AIkido Pharma Inc. (trading under the symbol DOMH), is a biotechnology company focused on developing small-molecule anti-cancer therapeutics and an antiviral platform. The company is primarily engaged in research and development and has license agreements for its intellectual property. Therefore, its major "customers" or partners are the entities with whom it has these agreements, rather than selling approved products directly to individuals or a broad market.
The company sells primarily to other companies and institutions through licensing agreements. Its major customers/partners include:
- Silo Pharma Inc. (Symbol: SILO)
- University of Texas
- University of Maryland Baltimore
- Wake Forest University Health Sciences
AI Analysis | Feedback
AI Analysis | Feedback
Anthony C. Hayes, Esq., Chief Executive Officer and Chairman of the Board
Anthony C. Hayes is the driving force behind Dominari Holdings Inc.'s expansion plans, overseeing the transformation of AIkido from a biotechnology company to a diversified corporate enterprise. He is an attorney, a former partner at an Am Law 100 firm, and co-founded and was the managing member of JaNSOME IP Management LLC, an intellectual property monetization consulting firm. Hayes received special recognition from President George W. Bush for creating the 'Wills For Heroes' program. He has also been involved in multimillion-dollar M&A acquisitions.
Tim Ledwick, Chief Financial Officer
Tim Ledwick brings more than two decades of public and private company CFO experience to Dominari. He was appointed as CFO effective October 1, 2025, and previously served as the Audit Committee Chair of Dominari from 2015-2025. Most recently, he provided CFO consulting services to a Nasdaq-listed public safety technology and services company (Nasdaq: WRAP). From 2011 until 2022, he was the Chief Financial Officer of SYFT, a private equity-backed company that was successfully sold to GHX in 2022. He has also held CFO positions at Dictaphone Corporation, Lernout & Hauspie Speech Products, Cross Media Marketing Corp, and Cityscape Financial Corp.
Kyle M. Wool, President
Kyle M. Wool serves as President to the Dominari Holdings Inc. Board of Directors and is the CEO of Dominari Financial Inc. and Dominari Securities. He has over 20 years of experience in global finance, including roles as a Managing Director at Oppenheimer & Co., Head of Wealth Management for their Asian branch, Executive Director at Morgan Stanley, and President of Revere Securities LLC.
Chris Devall, Chief Operating Officer
Chris Devall brings two decades of experience and expertise in various industries, including government procurement, manufacturing, and biotech, to his role as Chief Operating Officer.
Soo Yu, Special Projects Manager
Soo Yu serves as the Special Projects Manager for Dominari Holdings Inc.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Dominari Holdings Inc. (symbol: DOMH) maintains legacy investments in biotechnology through its Aikido Labs segment, despite primarily operating as a financial services firm. The addressable markets for its main biotechnology products, focusing on cancer therapeutics and an antiviral platform, are detailed below:
- Prostate Cancer Therapeutics: The global market size for prostate cancer therapeutics was estimated at approximately USD 17.0 billion in 2024 and is projected to reach about USD 31.99 billion by 2030. Other estimates place the market at USD 25.12 billion in 2025, with a projection to reach USD 106.86 billion by 2034.
- Pancreatic Cancer Therapeutics: The global pancreatic cancer treatment market was valued at around USD 2.92 billion in 2024 and is projected to reach approximately USD 5.84 billion by 2030. Another estimate indicates a market size of US$ 4.3 billion in 2026, with a projected growth to US$ 12.6 billion by 2033.
- Acute Myeloid Leukemia (AML) Therapeutics: The global acute myeloid leukemia treatment market was estimated at USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030. Another report estimates the market at USD 4.28 billion in 2026, with a projection to reach approximately USD 10.64 billion by 2035.
- Acute Lymphoblastic Leukemia (ALL) Therapeutics: The global acute lymphoblastic leukemia therapeutics market size was valued at USD 3.12 billion in 2023 and is projected to grow to USD 4.99 billion by 2030. Other analyses indicate the market was valued at USD 4.04 billion in 2026, expected to reach USD 5.53 billion by 2031.
- Antiviral Platform (including influenza, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2): The global antiviral drugs market was estimated at USD 60.6 billion in 2024 and is expected to grow to USD 85.4 billion in 2034. Another source estimates the market at USD 65.13 billion in 2026, with a projection to approximately USD 89.86 billion by 2035.
AI Analysis | Feedback
- Expansion of Financial Services Operations: Dominari Holdings Inc., primarily through its subsidiary Dominari Financial Inc., is strategically focused on wealth management, investment banking, sales and trading, and asset management. The company has explicitly stated its long-range goal to diversify into the financial services sector, actively recruiting new team members and building out operations to support this objective. This expansion of its core financial services activities is a key driver.
- Strategic Acquisitions in the Financial Services Industry: A core component of Dominari's growth strategy involves making strategic acquisitions within the financial services sector. For instance, Dominari Financial acquired a registered broker-dealer, Fieldpoint Private Securities, LLC, which was subsequently renamed Dominari Securities LLC, to bolster its financial services offerings. Continued strategic acquisitions are expected to expand its market reach and diversify its service portfolio.
- Launch and Growth of New Financial Products and Services: Dominari is actively developing and introducing new offerings within its financial services segment. An example is the joint venture between Dominari Financial and Heritage Strategies LLC, formed in May 2024, to offer various insurance products and services. These include life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services, which are anticipated to contribute to future revenue growth.
- Increased Capital Markets Activity and Underwriting: Dominari Securities is engaged in capital markets activities and underwriting. Its approval as a Limited Underwriting Member of NYSE in September 2025 further strengthens its position in this area. Reports indicate significant growth in this segment, with Dominari Securities raising over $1.4 billion year-to-date through capital markets activity and experiencing a 520% surge in Q2 2025 revenue for this area. This continued momentum in capital markets and underwriting is expected to be a substantial revenue driver.
AI Analysis | Feedback
Share Repurchases
- In January 2022, the board authorized a share repurchase program of up to $3 million.
- During 2022, the company repurchased approximately $3.1 million in shares, including 468,017 shares.
- In December 2022, a new $2 million share repurchase program was authorized, under which the company made purchases in late 2022 and early 2023.
Share Issuance
- In February 2022, the company agreed to issue and sell 11,000 shares of Series O Redeemable Convertible Preferred Stock in a registered direct offering.
- In August 2025, Dominari Holdings filed a shelf registration statement enabling the potential future offer and sale of up to $2 billion worth of common stock, preferred stock, or a combination thereof.
- In March 2026, stockholders approved increasing the shares reserved for issuance under the 2022 Equity Incentive Plan by 10 million shares, raising the total pool from 11,720,750 to 21,720,750 shares, with an additional automatic annual increase feature from 2027 to 2032.
Inbound Investments
- The company raised approximately $13.5 million subsequent to December 31, 2024, to fund its operations.
- As of September 30, 2025, Dominari held significant cash and marketable securities totaling $176.2 million, resulting in the withdrawal of a $2 billion shelf registration statement as additional capital was not required at that time.
Outbound Investments
- In January 2021, the company invested in Convergent Therapeutics, Inc., a firm focused on next-generation prostate cancer therapy. Subsequently, during 2021, the company also made investments in DatChat, Inc. (which resulted in a 600% return on investment), Tevva Motors, and Kerna Health ($1.0 million for 1,333,334 shares).
- In 2023, as part of its strategic shift to financial services, Dominari Financial completed the acquisition of Fieldpoint Private Securities, LLC, a broker-dealer and investment advisor.
- In 2024, Dominari Financial entered into a joint venture with Heritage Strategies LLC to establish Dominari Financial Heritage Strategies LLC, focusing on offering various insurance products and services.
Capital Expenditures
- Approximately $3.2 million of capital was deployed in 2022 to establish and operate its financial services subsidiary, Dominari Financial Inc., which included the acquisition of a broker-dealer.
- Dominari plans to continue expanding its financial services operations and seeks additional capital to support future growth and operational needs.
- The company aims to enhance stockholder value by pursuing opportunities outside its current business, including in the AI and Data Center sectors, while also providing management support to its subsidiaries for efficient and cost-effective operations.
Peer Outperformance in Diversified Capital Markets
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Investment Banking & Brokerage | 13 | 9.8% | 136.2% | 145.1% | IBKR 489% · SNEX 246% · HOOD 190% |
| Reinsurance | 6 | 22.3% | 82.1% | 128.8% | SPNT 162% · RGA 144% · MTG 129% |
| Diversified Banks | 13 | 35.0% | 138.3% | 113.5% | CM 158% · JPM 155% · RY 145% |
| Life & Health Insurance | 20 | 17.1% | 59.5% | 97.9% | JXN 516% · UNM 325% · FG 229% |
| Multi-Sector Holdings | 6 | 4.2% | 47.4% | 80.9% | JONE 361% · JEF 85% · BRK-B 81% |
| Property & Casualty Insurance | 42 | 11.5% | 74.3% | 69.0% | ASIC 2739900% · HRTG 436% · UVE 309% |
| Regional Banks | 265 | 27.6% | 88.5% | 67.1% | GCBC 378% · ESQ 353% · VBNK 328% |
| Multi-line Insurance | 9 | 13.4% | 86.5% | 56.6% | GNW 186% · L 102% · SLF 96% |
| Consumer Finance | 30 | 10.1% | 93.2% | 36.8% | ENVA 595% · EZPW 387% · FCFS 172% |
| Insurance Brokers | 16 | -11.4% | 1.8% | 25.3% | LIFE 631% · AJG 92% · ARX 89% |
| Financial Exchanges & Data | 15 | -0.2% | 21.5% | 24.6% | VIRT 219% · CBOE 158% · CME 79% |
| Asset Management & Custody Banks | 82 | -9.8% | 21.1% | 22.3% | WT 336% · SII 293% · VCTR 269% |
| Diversified Financial Services | 4 | -0.5% | 7.1% | 15.2% | FRHC 163% · EQH 95% · TMS -65% |
| Commercial & Residential Mortgage Finance | 12 | -39.6% | 29.8% | 7.4% | FNMA 498% · FMCC 476% · ESNT 66% |
| Specialized Finance | 3 | 15.7% | 49.7% | -6.8% | EFC 38% · CACC -7% · HASI -17% |
| Mortgage REITs | 33 | -10.9% | 11.2% | -12.9% | NREF 58% · RITM 53% · DX 41% |
| Transaction & Payment Processing Services | 15 | 3.6% | 1.2% | -38.7% | MA 73% · V 72% · CPAY 60% |
| Diversified Capital Markets ← | 21 | -20.0% | -0.4% | -44.0% | BTCS 629% · OPY 199% · LPLA 149% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Dominari Earnings Notes | 12/16/2025 | |
| null | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 39.13 |
| Mkt Cap | 25.3 |
| Rev LTM | 156 |
| Op Inc LTM | 0 |
| FCF LTM | -30 |
| FCF 3Y Avg | -21 |
| CFO LTM | -19 |
| CFO 3Y Avg | -12 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 37.2% |
| Rev Chg 3Y Avg | 101.5% |
| Rev Chg Q | 8.2% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Inc Chg LTM | -2.1% |
| Op Inc Chg 3Y Avg | -33.2% |
| Op Mgn LTM | -12.4% |
| Op Mgn 3Y Avg | -14.6% |
| QoQ Delta Op Mgn LTM | 2.2% |
| CFO/Rev LTM | -26.2% |
| CFO/Rev 3Y Avg | -29.6% |
| FCF/Rev LTM | -26.4% |
| FCF/Rev 3Y Avg | -39.3% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Dominari Financial | 123 | 21 | 2 | ||
| Legacy Holding Co | 0 | 0 | 0 | ||
| Single segment | 0 | 0 | |||
| Total | 123 | 21 | 2 | 0 | 0 |
| $ Mil | 2025 | 2024 | 2023 | 2010 | 2009 |
|---|---|---|---|---|---|
| Dominari Financial | 23 | -1 | -12 | ||
| Legacy Holding Co | -79 | -8 | -9 | ||
| Biospherics | -6 | ||||
| General | -3 | -2 | |||
| Health Sciences | 0 | 1 | |||
| BioSpherix | -8 | ||||
| Total | -56 | -9 | -22 | -8 | -9 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Dominari Financial | 21 | -1 | -12 |
| Legacy Holding Co | -44 | -14 | -11 |
| Total | -22 | -15 | -23 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Legacy Holding Co | 66 | 27 | 49 | ||
| Dominari Financial | 47 | 20 | 9 | ||
| Single segment | 76 | 103 | |||
| Total | 113 | 47 | 58 | 76 | 103 |
Price Behavior
| Market Price | $2.10 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -66.3% | |
| 50 Days | 200 Days | |
| DMA Price | $2.66 | $3.12 |
| DMA Trend | down | down |
| Distance from DMA | -21.1% | -32.7% |
| 3M | 1YR | |
| Volatility | 69.6% | 77.3% |
| Downside Capture | 253.69 | 324.41 |
| Upside Capture | 25.94 | 158.73 |
| Correlation (SPY) | 42.2% | 46.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.52 | 2.32 | 2.17 | 2.55 | 2.83 | 1.96 |
| Up Beta | 0.68 | 3.64 | 4.16 | 3.62 | 3.28 | 1.97 |
| Down Beta | 11.02 | 5.67 | 3.05 | 2.61 | 3.47 | 1.75 |
| Up Capture | -103% | -13% | 0% | 192% | 222% | 819% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 6 | 14 | 24 | 50 | 108 | 340 |
| Down Capture | 32% | 229% | 205% | 200% | 181% | 112% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 15 | 28 | 40 | 72 | 136 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DOMH | |
|---|---|---|---|---|
| DOMH | -56.1% | 77.2% | -0.73 | - |
| Sector ETF (XLF) | 8.8% | 14.6% | 0.35 | 29.7% |
| Equity (SPY) | 19.7% | 12.8% | 1.13 | 46.4% |
| Gold (GLD) | 24.6% | 29.2% | 0.75 | 21.4% |
| Commodities (DBC) | 43.8% | 20.3% | 1.67 | 3.4% |
| Real Estate (VNQ) | 9.1% | 13.6% | 0.39 | 11.0% |
| Bitcoin (BTCUSD) | -28.1% | 43.8% | -0.63 | 33.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DOMH | |
|---|---|---|---|---|
| DOMH | -26.3% | 100.1% | 0.08 | - |
| Sector ETF (XLF) | 10.1% | 18.4% | 0.41 | 17.3% |
| Equity (SPY) | 12.8% | 17.2% | 0.57 | 23.1% |
| Gold (GLD) | 19.1% | 18.8% | 0.82 | 9.1% |
| Commodities (DBC) | 10.7% | 19.5% | 0.43 | 5.3% |
| Real Estate (VNQ) | 1.7% | 18.9% | -0.01 | 14.7% |
| Bitcoin (BTCUSD) | 10.2% | 52.6% | 0.38 | 16.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DOMH | |
|---|---|---|---|---|
| DOMH | -25.5% | 125.3% | 0.24 | - |
| Sector ETF (XLF) | 13.6% | 22.1% | 0.56 | 2.4% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 4.9% |
| Gold (GLD) | 12.4% | 16.3% | 0.62 | 2.8% |
| Commodities (DBC) | 7.9% | 18.1% | 0.35 | -2.0% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.19 | 1.8% |
| Bitcoin (BTCUSD) | 63.7% | 66.2% | 1.03 | 6.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 03/28/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 08/11/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 03/25/2021 | 10-K |
| 09/30/2020 | 11/13/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/14/2020 | 10-Q |
| 12/31/2019 | 02/03/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
Insider Activity
Updated 7/28/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Devall, Christopher Franklin | COO | Direct | Sell | 12102025 | 3.85 | 45,000 | 173,061 | 560,341 | Form |
| 2 | Wool, Kyle Michael | President | Direct | Buy | 12102025 | 3.87 | 25,000 | 96,798 | 9,500,934 | Form |
| 3 | Hayes, Anthony | CEO | Direct | Buy | 12102025 | 3.87 | 23,000 | 89,054 | 6,779,205 | Form |
| 4 | Devall, Christopher Franklin | COO | Direct | Sell | 12052025 | 3.82 | 140,000 | 534,254 | 727,738 | Form |
| 5 | Devall, Christopher Franklin | COO | Direct | Sell | 12052025 | 4.21 | 40,000 | 168,548 | 1,393,479 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Devall, Christopher Franklin | COO | Direct | Sell | 12102025 | 3.85 | 45,000 | 173,061 | 560,341 | Form |
| 2 | Wool, Kyle Michael | President | Direct | Buy | 12102025 | 3.87 | 25,000 | 96,798 | 9,500,934 | Form |
| 3 | Hayes, Anthony | CEO | Direct | Buy | 12102025 | 3.87 | 23,000 | 89,054 | 6,779,205 | Form |
| 4 | Devall, Christopher Franklin | COO | Direct | Sell | 12052025 | 3.82 | 140,000 | 534,254 | 727,738 | Form |
| 5 | Devall, Christopher Franklin | COO | Direct | Sell | 12052025 | 4.21 | 40,000 | 168,548 | 1,393,479 | Form |
| 6 | Devall, Christopher Franklin | COO | Direct | Sell | 12052025 | 4.22 | 40,000 | 168,604 | 1,562,546 | Form |
| 7 | Lieberman, Ronald Craig | Direct | Buy | 9302025 | 0.00 | 21,613 | Form | |||
| 8 | Blattner, Gregory James | Direct | Sell | 9252025 | 0.00 | 14,409 | Form |
Industry Resources
| Financials Resources |
| Federal Reserve Economic Data |
| Federal Reserve |
| FDIC Data |
| American Banker |
| The Banker |
| Banking Technology |
| Diversified Capital Markets Resources |
| International Financing Review (IFR) |
| Financial News |
| Global Capital |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.